Vibrotactile Coordinated Reset for Parkinson's Patients of a More Variable Population
The purpose of our study is to evaluate Vibrotactile Coordinated Reset stimulation (vCR) and its effects on Parkinson's symptoms of a more variable population. vCR will be administered with a device called the Stanford Glove. vCR is expected to provide patients with a non-invasive alternative to the most widely used treatments such as Levodopa and or deep brain stimulation. Patients will be followed for two years.
|Condition or Disease||Intervention/Treatment||Phase|
Arms and Interventions
Patients will be asked to stimulate using a non invasive vibrotactile device.
Device: Stanford Glove
The vibrotactile device sends weak non-painful pattern type vibratory stimulus to the fingertips and is non-invasive. Some patient may experience dyskinesia which can me medicated with a decrease in Parkinson's medication
Primary Outcome Measures
- Change in Parkinsonian symptoms as defined by the change in Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III Score [6 months]
Change in MDS-Unified Parkinson's Disease Rating Scale Part III Scale Score Mean change in the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score. Minimum score - 0 indicates normal functioning Maximum score - 132 indicated severe impairment Lower scores indicate greater functionality and higher scores indicate severe impairment in functionality.
Age at the time of enrollment: 35 - 92 years
Idiopathic Parkinson's Symptoms between Hoehn and Yahr stages 2 to
Fluent in English
Comfortable with technology; can use a computer, check email, and access the internet; can initiate and engage in a virtual meeting for training and monitoring purposes.
Feels comfortable going off PD related medication during in person study visits
Lives in the United States
Any significant neuro-psychiatric problems, including acute confusional state, ongoing psychosis, or suicidal tendencies
Any current drug or alcohol abuse.
Participation in another drug, device, or biologics trial concurrently or within the preceding 30 days. Any other trial participation should be approved by the Principal Investigators.
Pregnancy, breast-feeding or wanting to become pregnant
Patient is unable to communicate properly with staff (i.e., severe speech problems)
Patient is taking a medication that may cause significant withdrawal effects
Contacts and Locations
LocationsNo locations specified.
Sponsors and Collaborators
- Stanford University
Study Documents (Full-Text)None provided.